Thymoquinone modifies CD4+:CD8+ ratio without affecting tumor necrosis factor‑α and interleukin‑1β levels in Wallerian degeneration crush injury rat model

Besin, Valentinus and Bajamal, Abdul Hafid and Nugraha, Jusak and Notopuro, Paulus Budiono and Naesilla, Naesilla and Humardani, Farizky Martriano (2024) Thymoquinone modifies CD4+:CD8+ ratio without affecting tumor necrosis factor‑α and interleukin‑1β levels in Wallerian degeneration crush injury rat model. Neuroscience and Behavioral Physiology. ISSN 0097-0549; E-ISSN 1573-899X

[thumbnail of Valentinus Besin_Thymoquinone modifies_Abstrak.pdf] PDF
Valentinus Besin_Thymoquinone modifies_Abstrak.pdf

Download (320kB)
[thumbnail of Valentinus Besin_Thymoquinone modifies.pdf] PDF
Valentinus Besin_Thymoquinone modifies.pdf
Restricted to Repository staff only

Download (1MB) | Request a copy
Official URL / DOI: https://link.springer.com/article/10.1007/s11055-0...

Abstract

Wallerian degeneration following nerve injury not only suppresses CD4+ T-cell responses but also pro- motes pro-inflammatory immunological responses through TNF-α and IL-1β. Recent research suggests that thymoquinone might enhance nerve recovery by exerting anti-inflammatory effects on both the innate and adaptive immune systems. This study aims to evaluate the effect of thymoquinone on neuroinflammation in a sciatic nerve crush injury, as represented by TNF-α, IL-1β, and the CD4+:CD8+ ratio. In this study, 126 crush injury Wistar rats were divided into three main groups: placebo, thymoquinone 100 mg/kg, and thymoquinone 250 mg/kg administered daily. Rats were euthanized at six distinct time points: 12, 18, and 24 hours, as well as on day-5, day-6, and day-7. TNF-α and IL-1β levels were assessed using the Enzyme- Linked Immunosorbent Assay (ELISA). The CD4+:CD8+ ratio in peripheral blood was determined via flow cytometry. No significant TNF-α differences was found between treatment and placebo groups. However, on day 6, IL-1β was significantly lower in the TQ 250mg/kg group than in the placebo (p=0.008). A similar but non-significant trend existed on days 6 and 7. On day 5, both TQ groups showed a higher, statistically significant CD4+:CD8+ ratio compared to placebo (p=0.007), a trend that continued to day 7 but not sta- tistically significant. Daily TQ administration did not consistently reduce TNF-α and IL-1ß levels. However, both doses elevated the CD4+:CD8+ ratio during the early stages of Wallerian degeneration, suggesting a potential benefit of TQ on nerve regeneration.

Item Type: Article
Uncontrolled Keywords: CD4+:CD8+ ratio · Nerve Injury · Interleukin-1β · Thymoquinone · Tumor Necrosis Factor-α · Wallerian degeneration
Subjects: R Medicine > R Medicine (General)
Divisions: Faculty of Medical
Depositing User: Ester Sri W. 196039
Date Deposited: 16 Jan 2024 04:59
Last Modified: 16 Jan 2024 04:59
URI: http://repository.ubaya.ac.id/id/eprint/45713

Actions (login required)

View Item View Item